All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
AACR 2020 | The rationale of combining PD1 blockade with two epigenetic modifiers for T-cell lymphoma treatment
The Lymphoma Hub was pleased to speak with Enrica Marchi, Center for Lymphoid Malignancies, Columbia University Medical Center, New York, US.
Enrica Marchi explains the rationale for the combination of PD1 blockade with epigenetic modifiers and its activity in preclinical models and early phase clinical trials for peripheral T-cell lymphoma (PTCL) treatment. She discusses the results of two multicenter, multi-arm, international study clinical trials — the DURABILITY trial (NCT03161223) and the EMBOLDEN trial (NCT03240211) — that assessed the value of adding an immune checkpoint inhibitor to an epigenetic modifier backbone regimen for the treatment of PTCL. She talks about the patient characteristics, safety profile, and clinical responses of both trials.
The rationale of combining PD1 blockade with two epigenetic modifiers for T-cell lymphoma treatment
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox